These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34195679)

  • 1. Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel.
    Samman KN; Mehanna P; Takla E; Grenier JC; Chan MY; Lopes RD; Neely ML; Wang TY; Newby LK; Becker RC; Lordkipanidzé M; Ruiz M; Hussin JG; Jolicœur EM
    Cell Rep Med; 2021 Jun; 2(6):100299. PubMed ID: 34195679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: Systematic review and meta-analysis.
    Misumida N; Aoi S; Kim SM; Ziada KM; Abdel-Latif A
    Cardiovasc Revasc Med; 2018 Sep; 19(6):689-694. PubMed ID: 29452843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
    Máchal J; Hlinomaz O
    Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor Does Not Improve Endothelial Dysfunction in Stable Survivors of Acute Coronary Syndrome.
    Lim S; Choo EH; Kim CJ; Choi IJ; Lee KY; Hwang BH; Lee JM; Chung WS; Chang K
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):442-449. PubMed ID: 31035775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
    Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
    J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
    Mshelbwala FS; Hugenberg DW; Kreutz RP
    J Thromb Thrombolysis; 2020 Oct; 50(3):619-627. PubMed ID: 32152791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry.
    Basra SS; Wang TY; Simon DN; Chiswell K; Virani SS; Alam M; Nambi V; Denktas AE; Deswal A; Bozkurt B; Ballantyne CM; Peterson ED; Jneid H
    J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29886424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
    Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
    Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.
    Mahaffey KW; Held C; Wojdyla DM; James SK; Katus HA; Husted S; Steg PG; Cannon CP; Becker RC; Storey RF; Khurmi NS; Nicolau JC; Yu CM; Ardissino D; Budaj A; Morais J; Montgomery D; Himmelmann A; Harrington RA; Wallentin L;
    J Am Coll Cardiol; 2014 Apr; 63(15):1493-9. PubMed ID: 24561148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.
    Wang TY; Kaltenbach LA; Cannon CP; Fonarow GC; Choudhry NK; Henry TD; Cohen DJ; Bhandary D; Khan ND; Anstrom KJ; Peterson ED
    JAMA; 2019 Jan; 321(1):44-55. PubMed ID: 30620370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.
    Ariotti S; Ortega-Paz L; van Leeuwen M; Brugaletta S; Leonardi S; Akkerhuis KM; Rimoldi SF; Janssens G; Gianni U; van den Berge JC; Karagiannis A; Windecker S; Valgimigli M;
    JACC Cardiovasc Interv; 2018 Aug; 11(16):1576-1586. PubMed ID: 29805112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-Analysis Comparing P2Y
    Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM
    Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet-related biomarkers and their response to inhibition with aspirin and p2y
    Lowenstern A; Storey RF; Neely M; Sun JL; Angiolillo DJ; Cannon CP; Himmelmann A; Huber K; James SK; Katus HA; Morais J; Siegbahn A; Steg PG; Wallentin L; Becker RC;
    J Thromb Thrombolysis; 2017 Aug; 44(2):145-153. PubMed ID: 28608165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis.
    Wang D; Yang XH; Zhang JD; Li RB; Jia M; Cui XR
    BMC Cardiovasc Disord; 2018 Nov; 18(1):217. PubMed ID: 30497387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk.
    Park KH; Jeong MH; Kim HK; Ki YJ; Kim SS; Choi DH; Koh YY; Ahn Y; Kim HS; Gwon HC; Rha SW; Hwang JY;
    J Korean Med Sci; 2021 Nov; 36(42):e268. PubMed ID: 34725976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular and Bleeding Risks in Acute Myocardial Infarction Newly Treated With Ticagrelor vs. Clopidogrel in Taiwan.
    Lee CH; Cheng CL; Kao Yang YH; Chao TH; Chen JY; Li YH
    Circ J; 2018 Feb; 82(3):747-756. PubMed ID: 29081474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
    Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
    Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.